ING Groep NV Has $24.87 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ING Groep NV reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 20.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,311 shares of the biopharmaceutical company’s stock after selling 7,484 shares during the period. ING Groep NV’s holdings in Regeneron Pharmaceuticals were worth $24,865,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the stock. Meyer Handelman Co. grew its position in Regeneron Pharmaceuticals by 11.4% during the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after acquiring an additional 435 shares during the last quarter. Stifel Financial Corp increased its stake in shares of Regeneron Pharmaceuticals by 12.2% in the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after buying an additional 3,385 shares in the last quarter. LPL Financial LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.3% in the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after buying an additional 3,479 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in Regeneron Pharmaceuticals by 32.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after buying an additional 1,221 shares in the last quarter. Finally, Monetary Management Group Inc. lifted its position in Regeneron Pharmaceuticals by 4.8% during the 3rd quarter. Monetary Management Group Inc. now owns 1,095 shares of the biopharmaceutical company’s stock worth $901,000 after buying an additional 50 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the sale, the chief executive officer now directly owns 466,877 shares in the company, valued at $457,179,964.71. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The disclosure for this sale can be found here. In the last three months, insiders sold 55,925 shares of company stock valued at $54,616,836. 8.83% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on REGN shares. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday. They issued an “outperform” rating and a $1,150.00 price objective for the company. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Truist Financial reissued a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, UBS Group upped their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $989.36.

View Our Latest Analysis on REGN

Regeneron Pharmaceuticals Trading Up 1.5 %

Shares of Regeneron Pharmaceuticals stock traded up $14.31 during trading hours on Friday, hitting $982.29. The company’s stock had a trading volume of 386,559 shares, compared to its average volume of 461,908. The company has a market capitalization of $108.23 billion, a PE ratio of 29.02, a price-to-earnings-growth ratio of 1.99 and a beta of 0.17. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The stock has a 50 day moving average of $942.68 and a 200 day moving average of $908.99. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.